Skip to main content
Clinical Trials/NCT02306473
NCT02306473
Completed
Early Phase 1

A Novel Non-invasive Way to Measure Airway Epithelial Permeability in Human Subjects

University of Rochester1 site in 1 country100 target enrollmentOctober 2015

Overview

Phase
Early Phase 1
Intervention
Mannitol
Conditions
Asthma
Sponsor
University of Rochester
Enrollment
100
Locations
1
Primary Endpoint
Airway permeability index (Urinary clearance of mannitol overtime)
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

This is a clinical trial designed to test the hypothesis that measuring the absorption and excretion of inhaled mannitol will provide a clinically useful marker of airway epithelial permeability in asthma.

Detailed Description

A cohort of subjects with asthma and healthy controls will be exposed to inhaled mannitol according to FDA approved protocols for bronchoprovocation. Mannitol will be measured in the bloodstream and urine and used to determine an airway permeability index. This is a proof of concept study and not a trial of new therapeutics.

Registry
clinicaltrials.gov
Start Date
October 2015
End Date
December 1, 2017
Last Updated
8 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Steve Nicholas Georas

Professor of Medicine

University of Rochester

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • \>5 pack year history of tobacco use or active smoking.
  • Other chronic or active lung diseases (e.g. COPD, pulmonary fibrosis, lung cancer)
  • History of significant renal insufficiency of liver disease
  • Asthma subjects with severe disease according to NAEPP guidelines (e.g. severe ongoing symptoms despite high-dose inhaled or oral glucocorticoids)
  • Asthma subjects with a baseline FEV1\<65% predicted
  • Asthma subjects unwilling or unable to withhold medications prior to testing
  • Pregnant women.

Arms & Interventions

Asthma

Subjects with asthma will be exposed to inhaled mannitol according to FDA approved protocols.

Intervention: Mannitol

Controls

Healthy control subjects will be exposed to inhaled mannitol according to FDA approved protocols.

Intervention: Mannitol

Outcomes

Primary Outcomes

Airway permeability index (Urinary clearance of mannitol overtime)

Time Frame: 24 hours

Urinary clearance of mannitol overtime

Secondary Outcomes

  • Absorption of mannitol (Absorption and clearance of mannitol from the bloodstream)(6 hours)

Study Sites (1)

Loading locations...

Similar Trials